|
Symposium
[Free Online] Advances in Cancer Therapeutics (Organized by PBSS and BioScience Forum)
Speakers:
Darrin Stuart, Scorpion Therapeutics; Jan Smith, Revolution Medicines; Shirley Liu, GV20 Therapeutics; Thierry Guillaudeux, CSO, Kineta; Sumith Kularatne, On Target Laboratories; Eric Blouin, Ipsos; Michael Pehl, Adcendo; Allen S. Yang, Summit Therapeutics; Samuel C. Blackman, Day One Biopharmaceuticals; Mark W. Frohlich, Indapta Therapeutics; Hequn Yin, Iovance Biotherapeutics; Jakob Dupont, Sofinnova Investments
Organizers:
Toby Freedman (Synapsis Search Recruiting and Author), Joe Carlino (Carlino Consulting), Donald McCarthy (Dawn Biopharma), Betty Chang (Summit Therapeutics), Wenfeng Xu (Chantibody Therapeutics), Snow Ge (BridgeBio Pharma), Shichang Miao (PBSS)
Date:
2024-08-14- 8/15/2024
Time:
8:30-13:15 Pacific Time
Registration fee:
Free
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-08-13
(it will close sooner if the seating cap is reached)
About the Topic
This two-day symposium will discuss the latest advances in the discovery and development of cancer therapeutics from leading pharmaceutical companies and promising biotech companies.
Preliminary Agenda
Day 1, August 14
| Time (PST) |
Topic |
Presenter(s) |
| 8:30-9:00 am |
PBSS and BioScience Forum Welcome and Introduction, Symposium Overview, Agenda Review |
Shichang Miao, PhD, PBSS; Joe Carlino, PhD, BioScienceForum |
| 9:00-9:35 am |
Discovery and Development of Mutant-Selective PI3Kα Inhibitors |
Darrin Stuart, PhD, CSO, Scorpion Therapeutics |
| 9:35-10:10 am |
Targeting Oncogenic RAS with Tri-Complex Inhibitors |
Jan Smith, PhD, CSO, Revolution Medicines |
| 10:10-10:45 am |
Integrated Computation and Genomics for Cancer Target and Drug Discovery |
Shirley Liu, PhD, CEO, GV20 Therapeutics |
| 10:45-11:00 am |
Break |
- |
| 11:00-11:35 am |
Immunosuppressive Myeloid Cells – an Emerging Target in Cancer Immunotherapy |
Thierry Guillaudeux, PhD, CSO, Kineta |
| 11:35 am-12:10 pm |
Targeted Drugs for Cancer |
Sumith Kularatne, PhD, Executive Vice President - R&D, On Target Laboratories |
| 12:10-12:45 pm |
Tumor Infiltrating Lymphocytes for Treating Solid Tumors |
Hequn Yin, PhD, SVP, Head of Research, Iovance Biotherapeutics |
| 12:45-1:15 pm |
Panel discussion |
All presenters |
Day 2, August 15
| Time (PST) |
Topic |
Presenter(s) |
| 8:30-8:35 am |
Welcome and Introduction, Symposium Overview |
Dean Wilson, PhD, PBSS |
| 8:35-9:10 am |
First-in-Class ADC for Hard-to-Treat Solid Tumor Cancers |
Michael Pehl, Dipl, CEO, Adcendo |
| 9:10-9:45 am |
Development of Bispecific Antibodies for Cancer |
Allen S. Yang, MD, PhD, CMO, Summit Therapeutics |
| 9:45-10:20 am |
From Concept to Proof: A New Model for Accelerating Pediatric Cancer Drug Development |
Samuel C. Blackman, MD, PhD, Founder and Head of R&D, Day One Biopharmaceuticals |
| 10:20-10:35 am |
Break |
- |
| 10:35-11:10 am |
Harnessing the Power of Naturally Occurring NK Cells to Fight Cancer & Autoimmune Disease |
Mark Frohlich, MD, CEO, Indapta Therapeutics |
| 11:10 am-11:45 pm |
Oncology Drug Approvals: A Review of Recent Practice-Changing Approvals and a Look at the Near-Term Pipeline |
Eric Blouin, BM, Senior Vice Presiden -Oncology, Ipsos |
| 11:45-12:20 pm |
The Outlook for Innovation in Cancer Therapeutics: A VC Perspective |
Jakob Dupont, MD, MA, Executive Partner, Sofinnova Investments |
| 12:20-12:50 pm |
Panel discussion |
All presenters |
2024-10-28, [Free Webinar] ASCO/ESMO Highlights: Latest Advances in Oncology Drug Development
|
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
|
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
|
2024-11-15, [In-Person] Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapies
|
2024-12-05, [Free Online] Innovative Mass Spectrometry and Related Technologies for Life Science and Drug Development
|
2024-12-13, Why All These New Modalities?
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
2025-02-06, [In-Person] Intellectual Property (IP) Strategies and Best Practices
|
2025-02-26, [In-Person] Demystifying Biopharma Business Development
|
2025-03-07, [In-Person] Clinical Trial Planning and Conduct: Fundamentals, Strategies and Best Practices
|
2025-03-27, [Free Online Workshop] Biotech Financing 101: from Angels, Government Agencies, Foundations and VCs
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Aroga Biosciences
Aroga Biosciences is an award-winning CRO specializing in scientific writing for nonclinical reports, INDs, CMC, and clinical documents.
|
PharmaResources
Top-tier small molecule CRO/CDMO offering comprehensive supports from Medicinal Chemistry, DMPK, and CMC to GMP manufacturing for commercialization.
|
Allucent
Bringing innovation to Biotech w/ClinPharm Modeling & Simulation services to inform dose, design, modeling + development strategies.
|
Submit a Text Ad
|